Vascular News and Research

RSS
Researchers receive funding to study care processes in patients beginning dialysis

Researchers receive funding to study care processes in patients beginning dialysis

PulmoBind product candidate has potential for early diagnosis of PH in pediatric population

PulmoBind product candidate has potential for early diagnosis of PH in pediatric population

Patients with BAI can be managed non-operatively with beta-blockade: Researchers

Patients with BAI can be managed non-operatively with beta-blockade: Researchers

Researchers compare effectiveness of IB and AMP in high-risk patients

Researchers compare effectiveness of IB and AMP in high-risk patients

Preoperative BB usage to help prevent POMI revealed at Vascular Annual Meeting

Preoperative BB usage to help prevent POMI revealed at Vascular Annual Meeting

Researchers find LEB or EV demonstrates faster rate of healing for larger wounds

Researchers find LEB or EV demonstrates faster rate of healing for larger wounds

Integra LifeSciences announces over 800 implantations of Vu a-POD fusion device

Integra LifeSciences announces over 800 implantations of Vu a-POD fusion device

Researchers compare clinical outcome of patients with smaller and larger AAAs after EVAR

Researchers compare clinical outcome of patients with smaller and larger AAAs after EVAR

New study assesses accuracy of indirect estimated radiation doses during eTAAA

New study assesses accuracy of indirect estimated radiation doses during eTAAA

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

MiMedx' HydroFix Vaso Shield receives FDA clearance for additional thicknesses and sizes

MiMedx' HydroFix Vaso Shield receives FDA clearance for additional thicknesses and sizes

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.